Skip to main content
SpringerLink
Log in

Industrieforum

  • Industrieforum
  • Published:
Uro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • nach Informationen von Merck/Pfizer

  • nach Informationen von Takeda

  • Lunch-Symposium „Behandlung des mUC — bereits auf dem Weg zur personalisierten Therapie?“, 71. Kongress der Deutschen Gesellschaft für Urologie e. V. (DGU); Hamburg, 20. September 2019; Veranstalter: Roche

  • nach Informationen von Sanofi Genzyme

  • Symposium „Immunonkologische Therapie beim fortgeschrittenen Urothelkarzinom — Überlebenserwartung neu definiert?“, 71. Kongress der Deutschen Gesellschaft für Urologie (DGU); Hamburg, 19. September 2019; Veranstalter: MSD

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Red,  Silke Wedekind & Michael Koczorek

Authors
  1. Red
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silke Wedekind
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Koczorek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Red, Wedekind, S. & Koczorek, M. Industrieforum. Uro-News 23, 56–57 (2019). https://doi.org/10.1007/s00092-019-3006-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-019-3006-3

Search

Navigation